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Abstract
Background: Two active compounds, baicalein and its glycoside baicalin were found in the dried root of
Scutellaria baicalensis Georgi, and reported to be neuroprotective in vitro and in vivo. This study aims to evaluate
the protective effects of baicalein on the rotenone-induced apoptosis in dopaminergic SH-SY5Y cells related to
parkinsonism.
Methods: Cell viability and cytotoxicity were determined by MTT assay. The degree of nuclear apoptosis was
evaluated with a fluorescent DNA-binding probe Hoechst 33258. The production of reactive oxidative species (ROS)
and loss of mitochondrial membrane potential (ΔΨm) were determined by fluorescent staining with DCFH-DA and
Rhodanmine 123, respectively. The expression of Bax, Bcl-2, cleaved caspase-3 and phosphorylated ERK1/2 was
determined by the Western blots.
Results: Baicalein significantly increased viability and decreased rotenone-induced death of SH-SY5Y cells in a dose-
dependent manner. Pre- and subsequent co-treatment with baicalein preserved the cell morphology and attenuated
the nuclear apoptotic characteristics triggered by rotenone. Baicalein antagonized rotenone-induced overproduction
of ROS, loss of ΔΨm, the increased expression of Bax, cleaved caspase-3 and phosphorylated ERK1/2 and the
decreased expression of Bcl-2.
Conclusion: The antioxidative effect, mitochondrial protection and modulation of anti-and pro-apoptotic proteins
are related to the neuroprotective effects of baicalein against rotenone induced cell death in SH-SY5Y cells.
Background
Parkinson’s disease (PD) is a neurodegenerative disease
mainly characterized by loss of dopaminergic neurons in
the substantia nigra pars compacta [1]. Although the
pathology of PD is not understood well, the neurotoxic
animal models of PD represent some key neurobeha-
vioral or pathological features [2]. Three neurotoxins, 6-
hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) and rotenone, are the
agents to induce parkinsonism in vitro and in vivo [3].
An extensive study of these models defined important
cellular actions of cell death and offered a basis for the
development of novel therapeutic strategies [4]. Rote-
none, a lipophilic pesticide, can cross cell membrane
easily to induce systemic inhibition of mitochondrial
complex I and cause selective nigrostriatal dopaminergic
degeneration [5]. Rotenone-induced apoptosis in human
neuroblastoma SH-SY5Y cells was mediated by the gen-
eration of mitochondrial reactive oxygen species (ROS)
[6].
The rotenone model of PD has been used for identifying
potential neuroprotective agents in recent years [7]. This
model would enable scientific re-evaluation of various her-
bals for treating PD [8] and facilitate the development of
novel anti-parkinsonian drugs [9]. Baicalein and its corre-
sponding glycoside baicalin are two flavonoid compounds
found in the dried root of Scutellaria baicalensis Georgi.
A series of studies demonstrated the neuroprotective
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any medium, provided the original work is properly cited.effects of baicalein or baicalin in experimental models of
Alzheimer’s disease [10,11], ischemic stroke [12-15] and
PD [16-19]. Baicalein was reported to be effective on 6-
OHDA models [18,20,21] and MPTP models [19,22] of
PD. This study aims to investigate the neuroprotective
effects of baicalein or baicalin on rotenone-induced cellu-
lar toxicities (SH-SY5Y cells) in vitro and in vivo.
Methods
Materials
Baicalein and baicalin (Figure 1) with purity > 98% were
purchased from Shanghai Innovative Research Center of
Traditional Chinese Medicine (SIRC/TCM). Stock solu-
tions (100 mM) were prepared in DMSO and diluted with
serum-free medium. Dulbecco’s Modified Eagle Medium
with Nutrient Mixture F-12 (DMEM/F-12), Fetal Bovine
Serum (FBS) and Penicillin-Streptomycin were purchased
from GIBCO BRL (Grand Island, NY, USA). 2,7-Dichloro-
fluorescein diacetate (DCFH-DA) and Rhodanmine 123
(Rh123) were purchased from Molecular Probes (Invitro-
gen, CA, USA). Rotenone, Hoechst 33258, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
( M T T ) ,R I P Ab u f f e r ,B C AP r o t e i nA s s a yK i ta n do t h e r
chemicals were obtained from Sigma-Aldrich (St. Louis,
MO, USA). PVDF membrane was purchased from Milli-
pore (MA, USA). Primary antibodies against Bax (D21),
Bcl-2 (C21), b-actin and horseradish peroxidase (HRP)-
conjugated secondary antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary
antibodies against phospho-p44/42 MAPK (ERK1/2)
(Thr202/Tyr204) and cleaved caspase-3 (Asp175) were
purchased from Cell Signaling (Beverly, MA, USA). ECL™
Western blotting detection system was purchased from
Amersham Biosciences (Piscataway, NJ, USA).
Cell culture and treatments
Human neuroblastoma SH-SY5Y cells (passage ≤ 25)
were cultured as described in our previous study [21]
and then treated with different concentrations of rote-
none, baicalein or baicalin respectively in serum-free
medium for 24 hours to determine their cytotoxicity. To
evaluate the protective effects, we pretreated SH-SY5Y
cells with different concentrations of baicalein or baica-
lin for 1 hour and subsequently rotenone was added to
the cells for another 24 hours. The final concentration
of DMSO in the medium was 0.5%, and showed no
cytotoxicity to the cells.
MTT assay
SH-SY5Y cells seeded on 96-well plates at 80-90% conflu-
ence were used in the MTT assay as described in our pre-
vious study [21]. In brief, the medium was removed after
the treatment. MTT solution (50 μl, 0.5 mg/ml in
DMEM/F12) was added to each well and incubated for
4 hours at 37°C. MTT lysis buffer containing 50 μl of 20%
SDS (sodium dodecyl sulfate), 50% DMF (N, N-dimethyl-
formamide), adjusted to pH4.7 by HCl (hydrogen chloride)
was then added before overnight incubation of the cells at
37°C to dissolve formazan. The absorbance at 570 nm was
measured by a microplate reader (Model 680, Bio-Rad
Laboratories, UK). The cell viability was expressed as per-
centage of the control.
Cellular morphology and nuclear apoptosis
SH-SY5Y cells were incubated with different concentra-
tions of baicalein in serum-free medium for 1 hour, fol-
lowed by the co-treatment with rotenone (20 μM) for
another 24 hours. Chromosomal DNA was stained with a
fluorescent DNA-binding probe Hoechst 33258 (5 μg/ml)
for 5 minutes, washed with PBS and then observed by a
Axiovert S-100 Zeiss fluorescent microscope (Carl Zeiss,
Zürich, Switzerland) at 20×. The morphological changes
were visualized by phase-contrast imaging at 20×.
ROS and mitochondrial membrane potential
SH-SY5Y cells were pretreated with different concentra-
tions of baicalein for 1 hour and then co-treated with rote-
none (20 μM) for another 6 hours in serum-free medium.
According to the protocols described in our previous
study [21], the fluorescent probes DCFH-DA and Rh123
were used to determine the generation of intracellular
ROS and mitochondrial membrane potential (ΔΨm),
respectively. The total cell counts and fluorescent intensity
were calculated with Image J software (ImageJ 1.45, http://
rsbweb.nih.gov/ij). Mean fluorescent intensity (MFI) was
calculated for each group using the following formula:
MFI = total ﬂuorescent intensity × 100/total cell counts
Western blots analysis
SH-SY5Y cells were pre-incubated for 1 hour with dif-
ferent concentrations of baicalein and then co-treated
with rotenone (20 μM) for another 24 hours in serum-
free medium. Total proteins were extracted using RIPA
Figure 1 The chemical structure of (A) baicalein and (B)
baicalin.
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Assay Kit. Denatured proteins (30 μg) were size fractio-
nated by 12.5% SDS-polyacrylamide gels. Proteins were
transferred to PVDF membrane at 80 V for 3 hours.
The blots were blocked for 1 hour at room temperature
in fresh blocking buffer (0.1% Tween-20 in Tris-buffered
s a l i n e ,p H 7 . 4 ,c o n t a i n i n g5 %B S A ) .T h em e m b r a n ew a s
incubated overnight at 4°C with primary antibodies
against Bax, Bcl-2, cleaved caspase-3 and phosphorylated
ERK1/2 at dilution of 1:1000. b- a c t i nw a su s e da sa
loading control. The membrane was incubated for
2 hours with HRP-conjugated secondary antibodies at a
dilution of 1:2000. Signals were detected using ECL™
Western blotting detection system. Protein bands were
semi-quantified by densitometric analysis using Image J
software.
Statistical analysis
Each experiment was performed at least three times, and
the results were presented as means or means ± standard
deviations (SD). One-way analysis of variance (ANOVA)
followed by Student-Newman-Keuls test for multiple com-
parison was performed using the SigmaPlot 11.0 software
packages (Systat Software Inc., San Jose, CA, USA). Exact
P values were unavailable due to the software features
(Additional file 1 provides a screen snapshot for example).
Dose dependence was visually determined from the dose-
response graphs. A probability value of P < 0.05 was con-
sidered to be statistically significant.
Results
In this study, we evaluated the effects of baicalein and bai-
calin on rotenone-induced cell death, nuclear apoptosis,
production of intracellular ROS, loss of ΔΨm, expressions
of Bax, Bcl-2 and caspase-3, and phosphorylation of
ERK1/2 in SH-SY5Y cells.
Cell death
The cytotoxicity of rotenone, baicalein and baicalin were
determined by MTT assay, Figure 2A shows that the cell
viability was decreased in a dose-dependent manner (P <
0.01) by the treatment with rotenone for 24 hours. Rote-
none (20 μM) triggered about 50% cell death and this con-
centration was chosen for subsequent experiments. Both
baicalein and baicalin showed no cytotoxicity at the con-
centrations ranged 10-100 μM. Figure 2B shows that bai-
calein increased cell viability by 20-40% (P <0 . 0 1 )a ta l l
the tested concentrations, compared with the control.
The effect of baicalein and baicalin on rotenone-induced
cell death was evaluated. Figures 2C-D show that pre- and
subsequent co-treatment of baicalein significantly inhib-
ited rotenone-induced cell death in a dose-dependent
manner (P < 0.01). Baicalein (25-100 μM) increased the
cell viability up to or even more than the control level (P <
Figure 2 Effects of baicalein and baicalin on rotenone-induced cell death in SH-SY5Y cells. Cells were incubated with increasing
concentrations of rotenone (A), baicalein and baicalin (B) respectively for 24 hours in serum-free medium (n = 6, *P < 0.01 versus control). Cells
were pretreated with baicalein (C) or baicalin (D) for 1 hour and then cotreated with 20 μM rotenone for 24 hours in serum-free medium (n = 6,
#P < 0.01 versus control, *P < 0.01 versus rotenone treatment). E: The morphological change was visualized by phase-contrast imaging. Scale bar:
50 μm.
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gical observations revealed that baicalein significantly
reversed the cellular damage triggered by rotenone, as
shown in Figure 2E. However, baicalin showed no statisti-
cally significant protective effect against rotenone-induced
cell death.
Nuclear apoptosis
Compared with the control, the apoptotic characteris-
tics induced by the rotenone treatment, such as
nuclear condensation and fragmentation, could be atte-
nuated by pre- and subsequent co-treatment with
increasing concentrations of baicalein (as shown in
Figure 3). The statistical data showed 4.29 ± 0.69 folds
of increase in the ratio of apoptotic cells triggered by
rotenone, which could be reduced to the control level
by pre- and subsequent co-treatment with increasing
concentrations of baicalein (P < 0.01). Baicalein treat-
ment for 24 hours had no significantly effect on
nuclear apoptosis.
Figure 3 Effects of baicalein (Bai) on rotenone (RT)-induced nuclear apoptosis. Cells were pretreated with Bai for 1 hour and then cotreated with
20 μM RT for 24 hours in serum-free medium. (A) Representative nuclear morphology. Scale bar: 50 μm. (B) Statistical analysis of apoptotic cells. At
least 600 randomly selected cells were counted in each experiment (n = 3,
#P < 0.01 versus control, *P < 0.01 versus RT treatment).
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Figure 4 demonstrates that rotenone treatment induced
2.19 ± 0.36 folds of increase in the intracellular ROS com-
pared with the control (P < 0.01). Pre- and subsequent co-
treatment with baicalein reduced the production of ROS
in a dose-dependent manner (P < 0.01) down to the con-
trol level. Baicalein treatment for 6 hours showed no
significant effect on ROS production as compared with
the control.
Loss of ΔΨm
The inhibition of complex I by rotenone may induce loss
of ΔΨm and the release of pro-apoptotic proteins [23]. As
shown in Figure 5, rotenone treatment led to about 2 folds
Figure 4 Effects of baicalein (Bai) on rotenone (RT)-induced ROS overproduction. Cells were pretreated with Bai for 1 hour and then
cotreated with 20 μM RT for 6 hours in serum-free medium. The ROS generation was determined by the mean fluorescent intensity (MFI) of
DCFH-DA. (A) Representative fluorescent images. Scale bar: 50 μm. (B) Statistical analysis. At least 600 randomly selected cells were counted in
each experiment (n = 3,
#P < 0.01 versus control, *P < 0.01 versus RT treatment).
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loss of ΔΨm. Pre- and subsequent co-treatment with bai-
calein significantly inhibited the loss of ΔΨmi nad o s e -
dependent manner (P < 0.01). Baicalein treatment for 6
hours showed no significant effect on ΔΨm as compared
with the control.
Expression of Bax, Bcl-2 and cleaved caspase-3
To further characterize the mechanism of baicalein inhi-
bition on rotenone-induced apoptosis, we determined
the effect of baicalein on the expression of anti- and
pro-apoptotic proteins by Western blots. As shown in
Figure 6, the expression of Bax and cleaved caspase-3
Figure 5 Effects of baicalein (Bai) on rotenone (RT)-induced loss of ΔΨm. Cells were pretreated with Bai for 1 hour and then cotreated with
20 μM RT for 6 hours in serum-free medium. The ΔΨm was determined by the mean fluorescent intensity (MFI) of Rh123. (A) Representative
fluorescent images. Scale bar: 50 μm. (B) Statistical analysis. At least 600 randomly selected cells were counted in each experiment (n = 3,
#P<
0.01 versus control, *P < 0.01 versus RT treatment).
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cantly decreased by the treatment with rotenone (20
μM) for 24 hours (P < 0.05), compared with the control.
Pre- and subsequent co-treatment with increasing con-
centrations of baicalein gradually restored the imbal-
anced expression profile of these proteins. Interestingly,
baicalein treatment alone for 24 hours could reduce the
base levels of Bax (0.86 ± 0.07) and cleaved caspase-3
(0.71 ± 0.09) (P < 0.05).
ERK1/2 phosphorylation
It was reported that rotenone induced ERK1/2 phos-
phorylation and neuronal degeneration in hippocampus
neurons [24]. Similar to this finding, we detected 2.47 ±
0.18 folds of increase in the expression of phosphory-
lated ERK1/2 in SH-SY5Y cells by treatment with rote-
none for 24 hours, as shown in Figure 6 (P < 0.05). Pre-
and subsequent co-treatment with baicalein reduced the
expression of phosphorylated ERK1/2 down to the con-
trol level in a dose-dependent manner. Baicalein treat-
ment alone for 24 hours could also significantly reduce
the base level of ERK1/2 phosphorylation.
Discussion
In the study, we evaluated the neuroprotective effects of
baicalein on rotenone-induced SH-SY5Y cell apoptosis.
In the neurotoxic models (6-OHDA and MPTP/MPP
+)
of PD, either baicalein or baicalin has been reported to
be effective [18,22,25]. However, we found that only bai-
calein showed a significant inhibition on rotenone-
induced cytotoxicity as demonstrated in Figure 2D. Choi
et al. [26] demonstrated that baicalein was protective
against endoplasmic reticulum (ER) stress-induced ROS
accumulation and apoptosis. The difference between bai-
calein and baicalin in antioxidative potential and cellular
permeability might contribute to their difference in cyto-
protective effects against ER stress-inducers [26]. These
two factors may also account for the different effects of
baicalein and baicalin on rotenone-induced cytotoxicity.
MTT cell viability assay showed that baicalein antago-
nized rotenone-induced cell death, which may be due to
the ability of baicalein in increasing the cell viability of
normal cells, as indicated in Figure 2B. The cell viability
was reduced to 62.64% (P < 0.01) by treatment with
rotenone alone for 24 hours while pre- and subsequent
co-treatment with baicalein (100 μM) increased the cell
viability to 137.01% (P < 0.01), as shown in Figure 2C.
Baicalein (100 μM) treatment alone induced 43.46%
increase (P < 0.01) in cell viability (Figure 2B) and the
difference in cell viability (Figure 2C) between rotenone
treatment alone (62.64%) and baicalein (100 μM) pre
and co-treatment (137.01%) is 74.37%, suggesting that
the cell proliferating activity of baicalein (43.46%
increase) does not account for its protection against
rotenone-induced cell death (74.37% increase). In other
words, the protection of baicalein against rotenone-
induced cell death may be independent of its cell prolif-
eration activity. These results suggested that baicalein
had protection against rotenone-induced cytotoxicity
independent of its cell proliferation activity.
O x i d a t i v ei n j u r yw a sp r o p o s e dt ob eap r i m a r y
mechanism of mitochondrial toxicity in the rotenone-
A B
Figure 6 Effects of baicalein (Bai) on rotenone (RT)-induced imbalance in the expression of Bax, Bcl-2, cleaved caspase-3 and phopho-
ERK1/2. Cells were pretreated with Bai for 1 hour and then cotreated with 20 μM RT for 24 hours in serum-free medium. Blots were stripped
and reprobed for b-actin as a loading control. (A) Representative protein bands. (B) Statistical analysis. The corresponding bar graph represented
data quantified from three independent experiments (n = 3,
#P < 0.05 versus control, *P < 0.05 versus RT treatment, **P < 0.05 versus control).
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Impairment of complex I activity by rotenone led to
excess ROS formation, which induced loss of ΔΨma n d
initiated apoptotic cell death [27,28]. It was reported
that baicalein suppressed the mitochondrial dysfunction
induced by hydrogen peroxide and 6-OHDA, and the
initiation of the loss of ΔΨm in PC12 cells and SH-
SY5Y cells, respectively [17,29]. This study confirmed
these findings that baicalein inhibited ROS production
and loss of ΔΨm triggered by rotenone in SH-SY5Y
cells, resulting in cellular resistance against the initiating
steps of apoptosis. This protection was mediated in part
by its antioxidative ability and preservation of mitochon-
drial function.
The balance of Bax and Bcl-2 proteins relates to the cell
viability [30]. Loss of ΔΨm increases the mitochondrial
permeability and results in the release of cytochrome c
from the mitochondria, which triggers activation of cas-
pase-9/3 and ultimate cell death [31]. In this study, we
found that baicalein restored the imbalance of the expres-
sion profiles of Bax, Bcl-2 and cleaved caspase-3; baicalein
treatment alone could also decrease the expression of Bax
and cleaved caspase-3; and modulation of the pro- and
anti-apoptotic proteins would be involved in the protective
effects of baicalein against rotenone-induced neurotoxicity.
Sustained ERK activation was reported to promote cell
death in neuronal cells treated with neurotoxins [32-34].
Figure 6 demonstrates that rotenone triggering signifi-
cant phosphorylation and activation of ERK1/2 was
antagonized by baicalein pretreatment, indicating that
inactivation of ERK1/2 pathway was involved in the neu-
roprotective effects of baicalein against rotenone-
induced neurotoxicity.
Conclusion
Inhibition of ROS overproduction, preservation of mito-
chondrial function, modulation of anti- and pro-apoptotic
proteins and inactivation of ERK1/2 pathway are related to
the neuroprotective effects of baicalein against rotenone-
induced apoptosis in dopaminergic SH-SY5Y cells.
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